Cerity Partners
NBIX icon

Cerity Partners’s Neurocrine Biosciences NBIX Stock Holding History

Cerity Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19M Buy
144,529
+10,770
+8% +$1.43M 0.03% 461
2025
Q4 		$19M Buy
133,759
+30,133
+29% +$4.37M 0.03% 428
2025
Q3 		$14.5M Buy
103,626
+44,852
+76% +$6.08M 0.02% 458
2025
Q2 		$7.39M Buy
58,774
+25,413
+76% +$2.91M 0.01% 650
2025
Q1 		$3.69M Sell
33,361
-8,376
-20% -$1.06M 0.01% 850
2024
Q4 		$5.29M Buy
41,737
+2,713
+7% +$336K 0.01% 691
2024
Q3 		$4.5M Buy
39,024
+11,622
+42% +$1.59M 0.01% 734
2024
Q2 		$3.77M Sell
27,402
-1,354
-5% -$186K 0.01% 694
2024
Q1 		$3.97M Buy
28,756
+24,392
+559% +$3.33M 0.01% 723
2023
Q4 		$575K Buy
+4,364
New +$502K ﹤0.01% 1212
2023
Q3 		– Sell
-4,214
Closed -$397K – 1607
2023
Q2 		$397K Buy
4,214
+365
+9% +$35.7K ﹤0.01% 1280
2023
Q1 		$390K Buy
3,849
+610
+19% +$63.5K ﹤0.01% 1411
2022
Q4 		$387K Buy
3,239
+533
+20% +$62.4K ﹤0.01% 1052
2022
Q3 		$288K Sell
2,706
-202
-7% -$20.5K ﹤0.01% 910
2022
Q2 		$284K Buy
+2,908
New +$268K ﹤0.01% 928

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cerity Partners's NBIX Position: Q1 2026 in Review

Cerity Partners increased its Neurocrine Biosciences (NBIX) stake by 8.1% in Q1 2026, buying an estimated $1.43M and bringing the position to 144,529 shares worth $19M. The position accounts for 0.03% of the portfolio, ranked #461.

Cerity Partners first reported a position in NBIX in Q2 2022 and has held it in 15 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Cerity Partners held 144,529 shares of Neurocrine Biosciences worth $19M as of Q1 2026.
  • Cerity Partners bought 10,770 Neurocrine Biosciences shares in Q1 2026, an estimated $1.43M.
  • Neurocrine Biosciences made up 0.03% of Cerity Partners's portfolio in Q1 2026, its #461 holding.
  • Cerity Partners first reported a position in Neurocrine Biosciences in Q2 2022 and has held it in 15 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.